[Study of survival using anistreplase (Eminase)].
Thrombolytic therapy has been one of the most important advances in the field of cardiovascular medicine. Several agents are available and research is continuing to develop new effective thrombolytics with a rapid onset of action. The efficacy of thrombolytic therapy can be evaluated by a number of criteria such as the reperfusion time, the incidence of coronary recanalisation, left ventricular function, and survival. Survival is certainly the parameter of choice for assessing any thrombolytic protocol. The aim of this paper is therefore to review the results of survival studies with Eminase, one of the new thrombolytic agents used in the treatment of acute myocardial infarction.
Murray
R G
RG
Department of Cardiology, East Birmingham District General Hospital, United-Kingdom.
D000368:Aged; D016255:Anistreplase; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy*; D010958:Plasminogen / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000627:therapeutic use*; D016019:Survival Analysis; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000379:methods*
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase
Etudes de survie avec l'anistreplase (Eminase).